As of 2025-09-16, the Intrinsic Value of Krystal Biotech Inc (KRYS) is 67.69 USD. This KRYS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 155.71 USD, the upside of Krystal Biotech Inc is -56.50%.
The range of the Intrinsic Value is 42.95 - 329.69 USD
Based on its market price of 155.71 USD and our intrinsic valuation, Krystal Biotech Inc (KRYS) is overvalued by 56.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 42.95 - 329.69 | 67.69 | -56.5% |
| DCF (Growth 10y) | 46.48 - 334.61 | 71.46 | -54.1% |
| DCF (EBITDA 5y) | 63.39 - 75.53 | 69.28 | -55.5% |
| DCF (EBITDA 10y) | 66.41 - 82.81 | 74.17 | -52.4% |
| Fair Value | 126.75 - 126.75 | 126.75 | -18.60% |
| P/E | 76.84 - 155.65 | 110.71 | -28.9% |
| EV/EBITDA | 97.97 - 155.60 | 119.96 | -23.0% |
| EPV | 4.69 - 2.51 | 3.60 | -97.7% |
| DDM - Stable | 49.25 - 222.42 | 135.83 | -12.8% |
| DDM - Multi | 28.66 - 102.80 | 45.08 | -71.0% |
| Market Cap (mil) | 4,506.25 |
| Beta | 0.53 |
| Outstanding shares (mil) | 28.94 |
| Enterprise Value (mil) | 4,152.42 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.63% |
| Cost of Debt | 5.00% |
| WACC | 6.15% |